|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
medical device
consumer health company
|
|
gptkbp:CEO
|
gptkb:Joaquin_Duato
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
478160104
|
|
gptkbp:dividendPaying
|
yes
|
|
gptkbp:foundedYear
|
1886
|
|
gptkbp:founder
|
gptkb:Robert_Wood_Johnson_I
gptkb:Edward_Mead_Johnson
gptkb:James_Wood_Johnson
|
|
gptkbp:fullName
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:headquartersLocation
|
gptkb:New_Brunswick,_New_Jersey,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
JNJ
|
|
gptkbp:industry
|
pharmaceuticals
medical devices
consumer health
|
|
gptkbp:ISIN
|
US4781601046
|
|
gptkbp:logo
|
Johnson & Johnson script logo
|
|
gptkbp:marketCap
|
over $400 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:Dow_Jones_Industrial_Average
gptkb:S&P_500
|
|
gptkbp:netIncome
|
$17.9 billion (2022)
|
|
gptkbp:notableEvent
|
COVID-19 vaccine development
Spin-off of Kenvue (2023)
Talcum powder litigation
|
|
gptkbp:numberOfEmployees
|
~130,000
|
|
gptkbp:product
|
gptkb:Listerine
gptkb:Aveeno
gptkb:Neutrogena
gptkb:Band-Aid
gptkb:Johnson's_Baby
gptkb:Motrin
gptkb:Nicorette
gptkb:Tylenol
gptkb:Zyrtec
gptkb:Imodium
|
|
gptkbp:revenue
|
$94.9 billion (2022)
|
|
gptkbp:spinOff
|
gptkb:Kenvue
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:JNJ
|
|
gptkbp:subsidiary
|
gptkb:DePuy_Synthes
gptkb:Ethicon
gptkb:Janssen_Pharmaceuticals
gptkb:Johnson_&_Johnson_Vision
|
|
gptkbp:website
|
https://www.jnj.com/
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson
|
|
gptkbp:bfsLayer
|
4
|